Regarding “EXCLUDER trial events are excluded from EXCLUDER trial report”  by McMurtry, Michael S. & Beckman, Joshua A.
stenosis despite a conservative approach to asymptomatic carotid
disease, in keeping with previous studies.1,4 Following a transient
ischemic attack, patients require duplex scanning after the event to
direct their management. Thus, for patients in whom a conserva-
tive approach is to be applied to asymptomatic restenosis or pro-
gression of contralateral disease, the value of duplex surveillance is
limited to research and audit. To clearly demonstrate a value of
duplex surveillance following carotid surgery would require an
appropriately powered randomized trial. Possibly more useful than
duplex surveillance might be the identification of biomarkers,
genetic markers or new imaging techniques that better identify
presently asymptomatic patients likely to experience a stroke.5,6
Jonathan Golledge, MChir
James Cook University
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Reply
We appreciate professor Golledge’s comments on one of the
more controversial issues concerning patients who undergo carotid
surgery—ie, the utility of ultrasound surveillance to manage the
progression of contralateral asymptomatic carotid disease.1
Golledge asserts that “an imaging finding is primarily of value
if it alters the clinical management of the patient.” Therefore,
taking Golledge’s words literally, because diabetic patients (being
at high vascular risk, according to current guidelines) are given
antiplatelet therapy, they should not have duplex ultrasonography
(DUS) until they suffer a stroke or other cardiovascular event,
because it is only then that a change of treatment would be
recommended—a bit late, in our opinion. According to the results
of the major randomized clinical trials, DUS follow-up would at
least pinpoint patients progressing to severe asymptomatic carotid
disease and likely to benefit from carotid endarterectomy. Contrar-
ily to the previous statement, Golledge himself admits that DUS
can noninvasively detect patients with complications potentially
hazardous to their health if not properly treated.
Golledge says that “ipsilateral restenosis. . .is believed to have a
benign natural history and therefore many clinicians treat such lesions
medically.”2 But how do we identify ipsilateral restenosis without
proper imaging? And how can the benign nature of such lesion be
established without a proper follow-up, including clinical assessment
and instrumental evaluation (DUS is the cheapest and safest method
available)?
The meta-analyses that Golledge mentions3,4 demonstrate that,
in expert hands, patients (especially men) with stenosis greater than
60% clearly benefit from carotid endarterectomy; considering the
burden of stroke on a patient and the community, we are sure
Golledge would agree on the merits of avoiding even a single stroke.
We agree that an appropriately powered randomized trial
would be preferable to our large but single-center study, and we
would be happy to collaborate with professor Golledge to set up
such a trial. Every patient deserves the best possible management,
wherever they live, which is why DUS (which is readily available
everywhere, cheap, and noninvasive) is useful in such a context (the
same can be hardly be said for the high-resolution, ultrasmall,
superparamagnetic iron oxide–enhanced magnetic resonance im-
aging5). We know of no specific biomarkers or genetic markers
capable of reliably identifying asymptomatic patients likely to
experience a stroke: C-reactive protein is one of many biomarkers
being studied as a predictor of cardiovascular events in patients
with carotid stenosis6, but it is aspecific for stroke, and the research
has been conducted on patients taking platelet inhibitors and/or
statins, which influence not only the occurrence of cardiocerebro-
vascular events but also the levels of acute-phase inflammatory
parameters such as C-reactive protein.
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Regarding “EXCLUDER trial events are excluded
from EXCLUDER trial report”
We read with interest the article of Peterson et al,1 which
reported 5-year data from a controlled trial of the EXCLUDER
device for endovascular repair (EVAR) of abdominal aortic aneu-
rysms but are concerned that their conclusions are not supported
by the presented data. The study was nonrandomized, as the
investigators state, but there are other large sources of confusion.
For example, of 235 patients selected for EVAR, only 128 patients
are included with no explanation of what happened to the remain-
ing 107 patients. Furthermore, though the investigator’s defini-
tion of adverse events is given in text, there is no description of
what these events actually were, who adjudicated them, or whether
they were blinded. The authors show that nearly 70% of patients
treated with open repair had a major adverse event within 30 days,
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a rate that seems preposterously high. If that is so, how can that
group have had a survival rate that is as good or better than the
EVAR group? These sources of confusion, as well as a lack of
disclosure of what themajor adverse events actually were, lead us to
conclude that the study does not show anything specific about
EVAR with the EXCLUDER device or that it has “fewer major
adverse events compared with open repair.”
Michael S. McMurtry, MD, PhD
Joshua A. Beckman, MD, MSc
Brigham and Women’s Hospital
Boston, Mass
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Reply
We are pleased that Drs McMurtry and Beckman were inter-
ested in the 5-year report1 and appreciate the opportunity to
respond. Of the original 235 test patients, 128 entered the final
5-year interval. The 107 test patients that were not available
included 54 patients who died, 30 patients who withdrew consent,
and 23 patients whowere unavailable for other reasons. Those with
experience performing these long-term studies recognize the dif-
ficulties of retaining enrollment of these elderly patients with
considerable medical problems. The original power analysis antic-
ipated a 6.5% annual mortality and 8% annual lost to follow-up. In
retrospect, these predictions were remarkably accurate, although
we had fewer patients lost to follow-up than predicted due to the
conscientious work of the site coordinators and investigators.
Despite the attrition, there were enough subjects in each group to
show a statistically significant difference between test and control
arms in freedom from any major adverse event after 5 years.
Many of your “other large sources of confusion” can be
clarified by reading the previously published and referenced 2-year
results.2 Specifically, “adverse events were stratified by severity into
minor and major adverse events by published criteria, and this
stratification was reviewed by a Clinical Events Committee.” Fur-
ther details on the criteria for adjudication and the categories of
these early events are provided in the methods section and Table
IV. Categories of later major adverse events are given in the Table
below. The Clinical Events Committee was a multispecialty group
that was blinded as much as possible and applied reporting stan-
dards published at the time of study initiation–the Sacks criteria.3
The blinding process helps avoid biased adjudication of adverse
events as your comment on “preposterously high” reveals that
there are clearly preconceived biases of the safety of the control
treatment. As detailed in the discussion, further analysis of minor,
major, and total complications was performed to determine
whether the Sacks criteria obscured differences between groups.
There were significantly fewer complications in the test group
regardless of the stratification by severity. In fact, the early major
adverse event rates using these published criteria were 14% of test
group vs 57% of control group, not “nearly 70%” that you claim.
The nonrandomized nature of this trial is a limitation that was
addressed by performing a multivariable analysis including known
differences in the two groups. This showed that test group was still
a strong independent predictor for fewer major adverse events.
Your query regarding the difference in major adverse events not
being associated with differences in mortality is simply answered by
the reality that vascular surgeons recognize and treat postoperative
complications effectively. These adverse events often prolong hospi-
talization and recovery as was demonstrated in differences in clinical
utility, but fortunately do not often lead to mortality.
The goal of this 5-year report was not to reiterate findings
previously found in the 2-year results, but rather to determine if
reinterventions and late events in the test group resulted in loss of
the early benefits seen after endovascular abdominal aortic aneu-
rysm repair. We stand by our conclusions that after 5 years,
endovascular repair has fewer major adverse events despite includ-
ing late reinterventions when compared with open repair.
Sincerely,
Table. Categories of late major adverse events
Year 1-after
30 d Year 2 Year 3 Year 4 Year 5
Test Control Test Control Test Control Test Control Test Control
Subjects evaluable 232 97 213 82 185 71 161 61 128 47
Subjects with one or more MAE 68 23 55 15 33 8 29 15 15 5
Bleeding complications 1 — 1 — 1 — 3 1 — —
Endoleak requiring intervention 13 — 10 — 2 — 3 — — —
Pulmonary complications 10 4 4 2 5 1 7 4 4 1
Cardiac complications 16 13 18 8 11 3 6 8 7 3
Genitourinary complications 6 2 — — — — 3 — 1 —
Sepsis 1 — — — 1 — 1 — — —
Neoplasm 7 1 8 2 5 3 4 — — —
Renal complications 5 — 4 1 3 1 2 3 1 —
Wound complications 8 3 1 1 2 2 1 1 — —
Bowel complications 8 3 7 1 2 1 2 2 1 1
Vascular complications 7 4 1 2 2 — 2 — 1 1
Neurologic complications 8 5 6 1 4 — 2 2 1 —
Other complications 12 2 11 3 8 1 7 3 1 —
Death (unknown cause) — — — — — — 1 — — —
Increase in aneurysm requiring
intervention (with or without endoleak) 1 — 8 — 1 — 6 — 2 —
MAE, Major adverse events.
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